Search results
Found 39 matches for
Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.
Health Economics & Outcomes Research
Arthritis Botnar Orthopaedics and trauma Statistics and epidemiology
Our research aims to improve people's health and wellbeing by making the most efficient use of health and social care resources. To achieve this, we use real-world data and mathematical models to evaluate the costs and consequences of applying different interventions over a period of time, often the entire lifetime of patients.
Dakin Group | Soft Tissue Joint Disease
Botnar Inflammation biology Orthopaedics and trauma Tissue remodelling and regeneration
The Dakin Group undertakes translational research focusing on identifying the cellular and molecular basis of inflammatory fibrotic soft tissue joint diseases, with research programmes on tendinopathy, frozen shoulder and knee arthrofibrosis. Understanding the cellular and molecular basis of these diseases will inform new therapeutic approaches targeting tissue resident stromal cells of the joint, to promote resolution of inflammatory fibrotic disease.